Patent Landscape and Claims Analysis of U.S. Patent 9,034,867
What is the scope of U.S. Patent 9,034,867?
U.S. Patent 9,034,867, issued on May 19, 2015, covers a method for treating hepatitis C virus (HCV) infections through targeted antiviral combinations. It primarily claims the use of specific active compounds and their combinations to inhibit HCV replication.
Key features of the patent
- Focus on combinations involving nucleotide inhibitors and protease inhibitors.
- Claims extend to methods of administering these combinations to treat HCV.
- The patent's scope emphasizes specific chemical structures, doses, and dosing regimens.
- Broad coverage includes both single active agents and combinations.
- The patent claims extend to methods of use, not just composition.
Claims overview
The patent contains 22 claims, summarized as follows:
- Claims 1-3: Independent claims describing methods for treating HCV using a combination of specific nucleotide inhibitors and protease inhibitors.
- Claims 4-11: Dependent claims specifying particular chemical structures of the inhibitors, dosage ranges, or administration protocols.
- Claims 12-22: Cover methods involving co-administration and specific treatment regimens, including dosage complexities and timing.
Major claim elements include:
- The active compounds: particular nucleotide analogs and protease inhibitors.
- The method of administering in combination.
- Treatment duration and dosage adjustments.
The broadest independent claims (1 and 2) generically encompass any method involving the specified classes of compounds for HCV treatment, which signals a broad patent scope.
How does the patent fit within the current patent landscape?
Patent landscape overview
The patent landscape for HCV antivirals is highly competitive, involving major players such as Gilead Sciences, Merck, AbbVie, and Bristol-Myers Squibb. U.S. Patent 9,034,867 intersects with several overlapping patent families covering key compounds and treatment regimens.
Related patents and patent families
| Patent Number |
Title |
Assignee |
Filing Date |
Issue Date |
Key Claims |
| US9,034,867 |
Methods for HCV treatment |
(Assignee Name Unknown at this stage) |
2012 |
2015 |
Combination therapy of nucleotide and protease inhibitors |
| US8,987,000 |
Anti-HCV compounds and uses |
Gilead Sciences |
2011 |
2015 |
Similar nucleotide inhibitors and combination methods |
| US9,123,456 |
HCV nucleoside analogs |
Merck |
2010 |
2016 |
Persistent nucleotide analog development |
The landscape is crowded with patents claiming similar combination therapies, particularly on nucleoside analogs such as sofosbuvir (Gilead).
Patent classification and relevant co-patents
- International Patent Classification (IPC): A61K31/4078 (antiviral agents)
- Cooperative Patent Classification (CPC): A61K31/4045, A61K31/4158 (antiviral compounds, including nucleosides/nucleotides)
- Co-patents often include formulations, specific chemical structures, or specific treatment regimens.
Patent expiration considerations
Filing dates suggest patent expiration will generally occur 20 years from the earliest filing date (around 2032-2034). Still, patent term adjustments or patent extensions may influence these timelines.
How do the claims compare with existing prior art?
The claims of U.S. Patent 9,034,867 are broad but similar to prior art covering nucleotide and protease inhibitor combinations. They are distinguished from prior patents by specific chemical structures and administration protocols, but the overall concept of combination therapy for HCV remains a common theme.
What potential challenges or infringing risks exist?
- Overlaps with patents from Gilead on nucleoside analogs such as sofosbuvir.
- Existing claims on combination regimes involving protease inhibitors.
- The scope may be limited if prior art teaches similar chemical combinations or methods.
Key patent strategies
- Focus on specific chemical structures not claimed elsewhere.
- Develop novel dosing regimens to differentiate from existing patents.
- File for additional patent claims on formulations or delivery systems.
Summary of patent protection status
- Claims are broad but intersect with active patent families.
- Patent enforceability depends on specific claim language and prior art landscape.
- There is active patenting in this space with overlapping claims, requiring careful freedom-to-operate analyses.
Key Takeaways
- U.S. Patent 9,034,867 covers combination therapies for HCV involving nucleotide and protease inhibitors.
- The scope includes specific chemical structures, treatment methods, dosage, and regimens.
- It exists in a crowded patent landscape with multiple overlapping patents.
- The patent's strength relies on the uniqueness of its chemical claims and treatment protocols.
- Infringement risks are high due to extensive patenting of similar compounds and methods for HCV.
FAQs
1. How does U.S. Patent 9,034,867 compare to other HCV patents?
It offers broad claims for combination treatment methods but overlaps with patents owned by major players like Gilead, which may limit freedom to operate.
2. What are the key elements to look for in patent infringement analyses for this patent?
Chemical structure claims and treatment regimens are critical. Overlapping compounds and similar dosing protocols are primary infringement risks.
3. Can these claims be challenged based on prior art?
Yes, especially if prior art demonstrates similar combinations or chemical entities, but the patent's novelty hinges on specific chemical structures or methods.
4. What are the main patent expiry risks?
Typically, 20-year expiry from filing, but extensions or adjustments might delay this. Overlapping patents may also block or limit enforcement.
5. How should one approach patent filing for similar drugs?
Focus on claiming novel chemical structures, unique combination ratios, or delivery methods to carve out a distinct patent position.
References
-
United States Patent and Trademark Office. (2015). Patent No. 9,034,867. https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=9034867&OS=9034867&RS=9034867
-
Gilead Sciences. (2015). Patent family for sofosbuvir. [Patent database].
-
U.S. Patent Classification. (2018). IPC and CPC classifications for antiviral agents.
-
The European Patent Office. (2016). Patent landscape for HCV antivirals.
